González-Cámpora R, Galera-Ruiz D, Armas-Padrón J R, Otal-Salaverri C, Galera-Davidson H
Department of Pathology, Hospital Universitario Virgen Macarena, University of Seville, Spain.
Diagn Cytopathol. 1998 Jul 1;19(1):4-8. doi: 10.1002/(sici)1097-0339(199807)19:1<4::aid-dc2>3.0.co;2-g.
Recently, the demonstration of DAP IV activity in thyroid cells aspirates has been proposed as an useful tool for the diagnosis of malignancy. We have studied the enzymatic activity of DAP IV, using the modified method of Lodja, in a series of 336 selected aspirates of the thyroid gland with the following cytologic diagnosis: 236 nodular hyperplasias, 60 follicular proliferations, eight Hashimoto's thyroiditis, eight Hürthe-cell proliferations, 20 papillary carcinomas, two anaplastic carcinomas, and two medullary carcinomas. The results were subjectively evaluated on the basis of staining intensity and extension in a minimum of 200 cells. Strong-to-moderate enzymatic activity with an extension of more than 40% of the cells were exclusively seen in follicular-cell derived carcinomas (papillary carcinoma, Hürthle-cell carcinoma, and follicular carcinoma). Medullary carcinoma, anaplastic carcinoma, and benign conditions were negative or weakly stained. Cytohistologic correlation in 88 patients operated on showed the following results: 26 nodular hyperplasia (18 nodular hyperplasia and eight follicular adenomas), 36 follicular proliferation (24 nodular hyperplasia, six, adenomas, three papillary carcinomas, three follicular carcinomas), two Hürthle-cell proliferation (one Hürthle-cell adenoma and one Hürthle-cell carcinoma), 20 papillary carcinomas, two medullary carcinomas, and two anaplastic carcinomas. DAP IV staining was moderate to strong and extensive in all malignant tumors initially diagnosed as follicular or Hürthle-cell proliferations. We conclude that DAP IV activity is present in malignant differentiated thyroid tumors of follicular cells (papillary carcinoma, follicular carcinoma, Hürthle-cell carcinoma), but it is identified neither in medullary carcinoma nor in anaplastic carcinoma. Therefore, its usefulness is restricted to the diagnosis of follicular-cell malignancies.
最近,甲状腺细胞抽吸物中DAP IV活性的检测已被提议作为诊断恶性肿瘤的一种有用工具。我们采用改良的洛贾方法,研究了336份经选择的甲状腺抽吸物中DAP IV的酶活性,这些抽吸物具有以下细胞学诊断结果:236例结节性增生、60例滤泡性增生、8例桥本甲状腺炎、8例许特莱细胞增生、20例乳头状癌、2例间变性癌和2例髓样癌。根据至少200个细胞的染色强度和范围对结果进行主观评估。仅在滤泡细胞来源的癌(乳头状癌、许特莱细胞癌和滤泡癌)中观察到强至中度酶活性且细胞范围超过40%。髓样癌、间变性癌和良性病变均为阴性或弱染色。88例接受手术的患者的细胞组织学相关性显示以下结果:26例结节性增生(18例结节性增生和8例滤泡性腺瘤)、36例滤泡性增生(24例结节性增生、6例腺瘤、3例乳头状癌、3例滤泡癌)、2例许特莱细胞增生(1例许特莱细胞腺瘤和1例许特莱细胞癌)、20例乳头状癌、2例髓样癌和2例间变性癌。最初诊断为滤泡性或许特莱细胞增生的所有恶性肿瘤中,DAP IV染色均为中度至强且广泛。我们得出结论,DAP IV活性存在于滤泡细胞的恶性分化甲状腺肿瘤(乳头状癌、滤泡癌、许特莱细胞癌)中,但在髓样癌和间变性癌中均未发现。因此,其用途仅限于滤泡细胞恶性肿瘤的诊断。